Passions

Creative writing

Music

Reading

Admissions and credentials

New York

Experience

Hengrui Pharma and GSK Enter Agreement to Develop up to 12 Medicines

July 27, 2025

Cooley advised Hengrui Pharma, a global pharmaceutical company, on its up to $12.5 billion agreement with GSK to develop up to 12 medicines to complement GSKs extensive respiratory, immunology and inflammation (RI&I) and oncology pipeline.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Frances Stocks Allen
Partner, London
Jiqiang Lin
Associate, New York
Freddy Yip
Associate, Hong Kong
Aaron Pomeroy
Partner, Colorado
David Wilson
Partner, London
Dr. Xiaozhen (Shawn) Yu
Partner, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
David Burns
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Robert Eisenbach
Of Counsel, San Francisco
Navya Dasari
Associate, New York
Rick Jantz
Associate, Santa Monica
Eerik Kukebal
Associate, London
Daniel Millard
Associate, London
Patrick Sharma
Associate, Santa Monica
Zhijing Yu
Associate, Singapore

Related Practices & Industries

Capstan Therapeutics Announces up to $2.1 Billion Acquisition by AbbVie

June 30, 2025

Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie.

Read more

Related contacts

Rama Padmanabhan
Partner, San Diego
Ken Rollins
Partner in Charge – San Diego, San Diego
Edmond Lay
Partner, San Diego
Charity Williams
Partner, San Diego
Lindsey O'Crump
Associate, Washington, DC
Megan Browdie
Partner, Washington, DC
Ross Eberly
Partner, Santa Monica
Christopher Kimball
Partner, Washington, DC
Alessandra Murata
Partner, Palo Alto
W. Chad Shear
Partner, San Diego
Jeffrey J. Tolin
Partner, New York
Stacey A. Bradford
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Randy Sabett
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Rachel Thorn
Of counsel, New York
Alexandria Ashour
Associate, San Diego
Navya Dasari
Associate, New York
Joshua Elefant
Associate, Palo Alto
Tony P. Guan
Associate, Santa Monica
Michelle Hunt
Associate
Emily Mok
Associate, Reston
Jonathan Perez-Reyzin
Associate, San Diego
Breanna Qin
Associate, Palo Alto
Christopher Suhler
Associate, Colorado
Novak Topalovic
Associate, San Diego
Heidi E. Wang
Associate, San Diego
Rubin Waranch
Associate, Colorado
Yuhan Wu
Associate, Palo Alto
Joanna Zhang
Associate, San Diego
Jessica Wade
Paralegal Specialist, San Diego

Related Practices & Industries

BioNTech Announces Global Collaboration Agreement With Bristol Myers Squibb

June 3, 2025

Cooley advised BioNTech SE, a global biotechnology company pioneering next-generation immunotherapies, on its global co-development and co-commercialization collaboration agreement with Bristol Myers Squibb for BioNTech’s antibody candidate BNT327. The transaction includes a $1.5 billion upfront payment and $2 billion total in noncontingent anniversary payments through 2028.

Read more

Related contacts

Kenneth Krisko
Partner, Reston
J. Brian Stalter
Special Counsel, New York
John Forrest
Associate, Boston
Arda Can Tekin
Associate, New York
Megan Browdie
Partner, Washington, DC
David Burns
Special Counsel, Washington, DC
Jonas Koponen
Partner, Brussels
Rachel Thorn
Of counsel, New York
Eric Blanchard
Partner, Boston
Christopher Kimball
Partner, Washington, DC
Joe Sandys
Special Counsel, London
Natasha Leskovsek
Of Counsel, Washington, DC
Navya Dasari
Associate, New York
Douglas Lyles
Senior Research Services & Access Analyst

Related Practices & Industries

Sirius Therapeutics Announces Collaboration With CRISPR Therapeutics

May 19, 2025

Cooley advised Sirius Therapeutics, a clinical-stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, on its strategic partnership to develop and commercialize siRNA therapies with CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Jiqiang Lin
Associate, New York
Navya Dasari
Associate, New York
Aaron Pomeroy
Partner, Colorado
Todd Gluth
Partner, San Diego
Rick Jantz
Associate, Santa Monica
Steve Przesmicki
Partner, San Diego
Robert Eisenbach
Of Counsel, San Francisco
Rachel Thorn
Of counsel, New York
David Burns
Special Counsel, Washington, DC
Eileen Marshall
Partner, Washington, DC
Jonathan Rivinus
Partner, Colorado

Related Practices & Industries

Jiangsu Hengrui Pharmaceuticals Announces License Agreement With Merck

March 25, 2025

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck (NYSE: MRK), known as MSD outside of the US and Canada, for HRS-5346, an investigational oral small molecule lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a phase 2 clinical trial in China.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Jiqiang Lin
Associate, New York
Andrew Epstein
Special Counsel, Seattle
Zhijing Yu
Associate, Singapore
David Burns
Special Counsel, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
Navya Dasari
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Russell Anderson
Partner, London
Megan Browdie
Partner, Washington, DC
Steve Przesmicki
Partner, San Diego

Related Practices & Industries

Memberships and affiliations

American Bar Association (ABA)